Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemotherapy in Advanced NSCLC
NCT00946712Phase 3Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2009
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of KL-140 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Overall Survival at 3 years and Progression-free Survival in EGFR FISH-positive Patients. Started Jul 2009; status: terminated.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00946712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00946712.